View all trials
Are you a member? Sign in above to view additional information
  • Study title
    AALL1231, A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed TLymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLY)
  • Protocol ID
    AALL1231
  • Disease
    Disease Type Disease Subtype
    Leukaemia All
    Lymphoma All
  • Eligibility criteria
  • Study Status
    Open
  • Location(s)
    Children's Hospital at Westmead
    • Centre Study Status:
      Open
    • Notes:
    John Hunter Children's Hospital
    • Centre Study Status:
      Open
    • Notes:
    Lady Cilento Children's Hospital
    • Centre Study Status:
      Open
    • Notes:
    Royal Children's Hospital Melbourne
    • Centre Study Status:
      Open
    • Notes:
  • Phase
    Phase 3
  • Study type
    Treatment
  • Diagnosis stage
    New diagnosis
  • Study open date
    03/09/2015
  • Study close date
    N/A
  • Study chair
    Dr. David Teachey
  • Sponsor
    Children's Oncology Group
Back to search results